Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

30.01.2018 | original article | Ausgabe 3-4/2018 Open Access

Wiener klinische Wochenschrift 3-4/2018

Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia

Wiener klinische Wochenschrift > Ausgabe 3-4/2018
MD Florian Huemer, MD, PhD Lukas Weiss, MD Viktoria Faber, MD Daniel Neureiter, MD Alexander Egle, MD Klaus Geissler, MD, PhD Daniela Voskova, MD Armin Zebisch, MD Sonja Burgstaller, MD Angelika Pichler, MD Reinhard Stauder, MD Wolfgang Sperr, MD Alois Lang, MD Michael Pfeilstöcker, MD Sigrid Machherndl-Spandl, MD Margarete Stampfl, MD Richard Greil, MD, MSc Lisa Pleyer
Wichtige Hinweise
F. Huemer and L. Weiss contributed equally to this work


Chronic myelomonocytic leukaemia is a rare disease and data on the treatment are often extrapolated from myelodysplastic syndrome studies. Although several scores exist for the prognosis of overall survival in chronic myelomonocytic leukaemia, so far there is no designated score for the prediction of the time to first treatment. We tested clinical parameters and cytogenetic information for their ability to predict the time to first treatment in our single center cohort of 55 unselected consecutive chronic myelomonocytic leukaemia patients. In multivariate analysis we identified elevated lactate dehydrogenase (≥223 U/l), higher bone marrow blast percentage (≥7.5%) and thrombocytopenia (<55 G/l) at initial diagnosis as the most relevant parameters for the time to first treatment. Using these three parameters we developed a risk score that efficiently estimates the time to treatment initiation with azacitidine or hydroxyurea (p < 0.001; log-rank). In the high-risk group (≥2 risk factors) 85% of patients required treatment within 1 year, whereas this was the case in 48% in the intermediate-risk (1 risk factor) and in 0% in the low-risk group (0 risk factors). Our risk model was validated in an external test cohort of 65 patients and may serve as a simplified and easily applicable tool for identifying patients who may not require early treatment initiation.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3-4/2018

Wiener klinische Wochenschrift 3-4/2018 Zur Ausgabe

MUW researcher of the month

MUW researcher of the month